A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus infections—the first in the world to be completed—yields disappointing results, but some doctors are not discouraged.

Almost 40 scientists have signed an open letter, citing odd patterns in the data and a lack of transparency after authors withheld the full data.

The hold will likely delay trial results, and scientists say the pause is proof that safety protocols in clinical trials are working as they should.

A meta-analysis of seven randomized controlled trials concludes that dexamethasone and other corticosteroids reduce 28-day mortality in seriously ill patients.

After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.

UPenn’s Katharine Bar discusses ongoing clinical trials to explore the efficacy of treating patients with plasma from individuals who have recovered from an infection.

In clinical studies worldwide, researchers are testing the possibility that supplements of the vitamin could prevent or decrease the severity of SARS-CoV-2 infections.

Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.

Upon seeing pregnant women sick with COVID-19 at a University of Pennsylvania hospital, researchers there wrote trial protocols for blood transfusions to treat the disease that include expecting mothers.